Affimed Announces Presentations on its AFM13 Innate Cell Engager at the 62nd American Society of Hematology Annual Meeting an...
November 04 2020 - 4:05PM
Heidelberg, Germany, November 4, 2020 – Affimed
N.V., (NASDAQ: AFMD) a clinical stage biopharmaceutical company
committed to giving patients back their innate ability to fight
cancer, announced today that two abstracts highlighting data
related to the company’s lead innate cell engager (ICE®), AFM13,
have been accepted for poster presentation at the virtual 62nd
American Society of Hematology (ASH) Annual Meeting and Exposition
being held December 5-8, 2020.
AFM13 is a first-in-class tetravalent, bispecific ICE® built on
Affimed’s Redirected Optimized Cell Killing (ROCK®) platform – the
most clinically advanced technology for designing innate immunity
therapies that can be tailored to specific patient populations and
tumor types. AFM13 works by binding to CD30 on tumor cells and to
CD16A on innate immune cells, engaging the patient’s immune system
in fighting cancer through NK cells and macrophages.
Details of presentations:
Poster presentation 1:
Title: Clinical and Biological Evaluation of
the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in
Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous
Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)
Abstract: 2971
Authors: Sawas A., Chen P.-H., Lipschitz M.,
Rodig S., Vlad G.
Date: December 7, 2020, 7:00 AM-3:30 PM
Final analysis of the AFM13 monotherapy study in patients with
relapsed or refractory CD30-positive lymphoma with cutaneous
presentation showed a high Objective Response Rate (ORR) of 40
percent with demonstrated therapeutic activity after brentuximab
vedotin failure. Response to AFM13 was correlated with an increase
in NK cell activation and tumor infiltration, demonstrating that
AFM13 modulates the NK cell population and that such changes are
associated with patient benefit.
Poster presentation 2:
Title: AFM13 in patients with relapsed or
refractory Hodgkin Lymphoma: Final results of an open-label,
randomized, multicenter phase II trial
Abstract: 2079
Authors: Momotow J., Sasse S., Plütschow A.,
Hüttmann A., Basara N., Könecke C., Martin S., Bentz M.,
Grosse-Thie C., Thorspecken S., De Wit M., Kobe C., Dietlein M., v.
Tresckow B., Fuchs M., Borchmann P., Engert A.
Date: December 6, 2020, 7:00 AM-3:30 PM
In this final trial analysis (NCT02321592), evaluating AFM13 in
a heavily pretreated patient population with classical Hodgkin
lymphoma (n=25), where patients were relapsed/refractory to
standard therapies including brentuximab vedotin and PD-1, an
objective response rate of 16.6% was observed, including 1 complete
and 3 partial responses. Stable and progressive disease was
documented in 6 and 14 patients, respectively. The trial was
terminated prematurely due to lack of recruitment. Therefore, no
statistical analyses were possible, and the report of the results
is of descriptive nature. Treatment with AFM13 was
well-tolerated.
Full abstracts of the presentations are published in a special
online-only issue in the journal Blood, a publication of the
American Society of Hematology.
For more details about the ASH Virtual Annual Meeting please
visit: https://www.hematology.org/meetings/annual-meeting.
About AFM13
AFM13 is a first-in-class CD30/CD16A ROCK®-derived bispecific
innate cell engager (ICE®) that induces specific and selective
killing of CD30-positive tumor cells by engaging and activating
natural killer (NK) cells and macrophages, thereby leveraging the
power of the innate immune system. AFM13 is Affimed’s most advanced
ICE® clinical program, and it is currently being evaluated as a
monotherapy in a registration-directed trial in patients with
relapsed/refractory peripheral T-cell lymphoma (REDIRECT). The
study is actively recruiting and can be found at
www.clinicaltrials.gov using the identifier NCT04101331.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology
company committed to giving patients back their innate ability to
fight cancer. Affimed’s fit-for-purpose ROCK® platform allows
innate cell engagers to be designed for specific patient
populations. The company is developing single and combination
therapies to treat hematologic and solid tumors. The company is
currently enrolling patients into a registration-directed study of
AFM13 for CD30-positive relapsed/refractory peripheral T cell
lymphoma and into a Phase 1/2a dose escalation/expansion study of
AFM24 for the treatment of advanced EGFR-expressing solid tumors.
For more information, please visit www.affimed.com.
Affimed Investor and Media Contact
Alex Fudukidis Head of Investor Relations
a.fudukidis@affimed.com
+1 (917) 436-8102
Mary Beth Sandin Head of Marketing and Communications
m.sandin@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Sep 2023 to Sep 2024